塞力斯医疗科技集团股份有限公司 董事会战略委员会实施细则 塞力斯医疗科技集团股份有限公司 董事会战略委员会实施细则 （2025年8月） 第一章 总则 第一条 为适应塞力斯医疗科技集团股份有限公司（以下简称"公司"）战 略发展需要，增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加 强决策科学性，提高重大投资决策的效益和决策的质量，完善公司治理结构，根 据相关法律法规及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公 司章程》"）的规定，特制定本细则。 第二条 董事会战略委员会是董事会按照股东会决议设立的专门工作机构， 主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会成员由五名董事组成，其中应至少包括一名独立董事。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第五条 战略委员会设召集人（即主任委员）一名，由公司董事长担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，可以连选连任。 期间如有委员不再担任公司董事职务，自动失去委员资格，并由委员会根据上述 第三至第五条规定补足委员人 ...

塞力斯医疗科技集团股份有限公司 独立董事专门会议工作制度 塞力斯医疗科技集团股份有限公司 《中华人民共和国证券法》 《上市公司独立董事管 理办法》 《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等法律、行政法规、部门规章、规范性文件以及《塞力 斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定，特制 定本制度。 第二条 公司应当定期或者不定期召开全部由独立董事参加的会议（以下简 称"专门会议"）。专门会议应当由过半数独立董事共同推举一名独立董事召集和 主持；召集人不履职或者不能履职时，两名及以上独立董事可以自行召集并推举 一名代表主持。 公司应当为独立董事专门会议的召开提供便利和支持。 独立董事专门会议工作制度 （2025 年 8 月） 第一条 为进一步完善塞力斯医疗科技集团股份有限公司（以下简称"公司"） 治理结构，充分发挥独立董事作用，促进公司的规范运作，维护公司整体利益， 根据《中华人民共和国公司法》 （六）公司被收购时，董事会针对收购所作出的决策及采取的措施； 第三条 独立董事召开专门会议应于会议召开前三日通知全体独立董事。因 情况紧急， ...

General Principles - The purpose of the implementation rules is to establish a sound assessment and compensation management system for the board of directors and senior management of the company, improving corporate governance structure [2] - The Compensation and Assessment Committee is a specialized working body established by the board of directors and is accountable to the board [2] Composition of the Committee - The Compensation and Assessment Committee consists of three directors, with independent directors making up more than half [4] - The committee members are nominated by the chairman, more than half of the independent directors, or one-third of all directors, and elected by the board [4] - The committee has a convener (chairperson) who is an independent director, responsible for leading the committee's work [6] Responsibilities and Authority - The committee is responsible for formulating assessment standards for directors and senior management, reviewing compensation policies, and making recommendations to the board on various matters [6] - The committee's proposed compensation plans for directors must be approved by the board and submitted for shareholder approval before implementation [10] - The committee must conduct an annual review of the compensation decision-making process and report findings to the board [11] Decision-Making Procedures - The committee's working group is responsible for preparing materials related to compensation and assessment decisions [12] - The assessment process includes self-evaluation by directors and senior management, followed by performance evaluations conducted by the committee [13] Meeting Rules - Meetings of the committee are called as needed, with notifications sent three days in advance, unless urgent [10] - A quorum requires attendance from at least two-thirds of the committee members, and decisions must be approved by a majority [15] - Meeting records must be kept, and confidentiality obligations apply to all attendees [22][24] Supplementary Provisions - The rules take effect upon approval by the board and are subject to relevant national laws and regulations [26][27] - The board holds the authority to interpret these rules [28]

塞力斯医疗科技集团股份有限公司 董事会提名委员会实施细则 塞力斯医疗科技集团股份有限公司 第三章 职责权限 第七条 提名委员会负责拟定董事、高级管理人员的选择标准和程序，对董 事、高级管理人员及其任职资格进行遴选、审核，并就下列事项向董事会提出建 议： 董事会提名委员会实施细则 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"）领 导人员的产生,优化董事会和高级管理层的组成,完善公司治理结构,根据相关法 律法规及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，特制定本细则。 第二条 董事会提名委员会是董事会设立的专门工作机构,对董事会负责。 第二章 人员组成 第三条 提名委员会成员由 3 名董事组成，独立董事应当过半数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名,并由董事会选举产生。 第五条 提名委员会设召集人（即主任委员）一名,由独立董事委员担任,负 责主持委员会工作；召集人在委员内选举,并报请董事会批准产生。 第六条 提名委员会任期与董事会任期一致,委员任期届满,可以连选连任。 期间如 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-072 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 全体董事均亲自出席本次董事会； ? 无董事对本次董事会议案投反对/弃权票； ? 本次董事会全部议案已获通过。 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年 8 月 17 日 以邮件方式发送第五届董事会第二十次会议通知，会议于 2025 年 8 月 27 日在公 司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应到董事 8 人，实到 董事 8 人，会议由董事长温伟先生主持，公司全体监事和高级管理人员列席了会 议。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《公 司法》等相关法律法规和《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： 表决结果：有效表决票共 8 票，其中同意票为 8 票，反对票为 ...

Meeting Overview - The supervisory board of the company held its ninth meeting on August 27, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][2] - All resolutions proposed during the meeting were approved unanimously, with no votes against or abstentions [1][2] Financial Reporting - The supervisory board reviewed and approved the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review processes complied with relevant laws, regulations, and internal management systems [1] - The board stated that the information contained in the semi-annual report accurately reflects the company's financial status and operational results, with no false statements or significant omissions identified [1] Fund Utilization - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, affirming that the situation aligns with regulatory rules and guidelines [2] - The report's content was deemed truthful, accurate, and complete, with no misleading statements or significant omissions found [2]

New Stock Offerings - Fushun Special Steel (600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] - Dongxin Co., Ltd. (688110) reported severe abnormal fluctuations on August 16, 2025[1] - Broadcom Integrated (603068) announced abnormal fluctuations on August 29, 2025[1] Market Alerts - ST Guohua (000004) and ST Gohong (000851) both reported abnormal fluctuations on August 29, 2025[1] - ST Huayang (603825) and ST Zhongji (000972) also indicated abnormal fluctuations on August 29, 2025[1] - ST Yanzhen (603389) reported abnormal fluctuations on August 26, 2025[1] Company Announcements - Zhaoxin Technology (603377) announced abnormal fluctuations on August 27, 2025[1] - Longyang Electronics (301396) reported significant fluctuations on August 28, 2025[1] - ST Dongshi (603377) indicated abnormal fluctuations on August 22, 2025[1]

Group 1: Shuoshi Biotech - Shuoshi Biotech reported a significant decline in net profit for the first half of 2025, with a net profit of 3.99 million yuan, down 86.35% year-on-year [1] - The company’s non-recurring net profit was -28.05 million yuan, a staggering decrease of 1219.78% year-on-year [1] - Eight senior executives voluntarily reduced their salaries by 5% to 50% to demonstrate solidarity during challenging times, indicating a need for innovation and market expansion to find new profit growth points [1] Group 2: BeiGene - BeiGene announced that the European Commission has approved its PD-1 monoclonal antibody, Tislelizumab, for use in neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence [2] - This approval marks a significant step for the internationalization of domestic PD-1 therapies, benefiting patients in Europe [2] Group 3: Shenzhou Cell - Shenzhou Cell reported a revenue of 972 million yuan for the first half of 2025, a decrease of 25.5% year-on-year, with a net profit of -33.77 million yuan, down 126.87% [3] - The second quarter saw a revenue of 452 million yuan, a decline of 34.66% year-on-year, and a net profit of -97.54 million yuan, down 289.37% [3] - Despite the revenue and profit decline, the company is actively advancing its R&D pipeline and exploring international markets [3] Group 4: Sali Medical - Sali Medical reported a revenue of approximately 584 million yuan for the first half of 2025, a decrease of 40.2% year-on-year, with a net loss of approximately 56.12 million yuan [4] - The company’s revenue and gross profit declined due to the transfer of some subsidiaries and challenges in its transformation, compounded by slow accounts receivable collection and difficulties in business renewals [4] - The company needs to accelerate its transformation efforts to improve performance [4]

Group 1 - Shuoshi Biotech reported a significant decline in net profit for the first half of 2025, with a net profit of 3.99 million yuan, down 86.35% year-on-year, and a non-recurring net profit of -28.05 million yuan, down 1219.78% year-on-year [1] - Eight senior executives, including the honorary chairman and the chairman, voluntarily reduced their salaries by 5% to 50%, demonstrating a commitment to overcoming current challenges [1] - The company faces pressure from industry-wide price reductions and tax rate adjustments, leading to a decline in gross margin, necessitating a focus on innovation and market expansion for future growth [1] Group 2 - BeiGene announced that the European Commission has approved its PD-1 monoclonal antibody, Tislelizumab, for use in neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence [2] - This approval marks a significant step for the internationalization of domestic PD-1 therapies, benefiting patients in Europe [2] Group 3 - Shenzhou Cell reported a revenue of 972 million yuan for the first half of 2025, a decrease of 25.5% year-on-year, with a net profit of -33.77 million yuan, down 126.87% year-on-year [3] - The second quarter saw a revenue of 452 million yuan, down 34.66% year-on-year, and a net profit of -97.54 million yuan, down 289.37% year-on-year [3] - Despite the revenue decline, the company is actively advancing its R&D pipeline and exploring international markets, indicating potential for future growth [3] Group 4 - Sali Medical reported a revenue of approximately 584 million yuan for the first half of 2025, a decrease of 40.2% year-on-year, with a net loss of approximately 56.12 million yuan [4] - The company experienced a significant increase in net loss compared to the previous year, where the net loss was approximately 477,000 yuan [4] - Challenges include slow accounts receivable collection and difficulties in business renewals, necessitating a faster transformation to improve performance [4]

每经AI快讯，塞力医疗（SH 603716，收盘价：33.1元）8月29日发布公告称，公司第五届第二十次董事 会会议于2025年8月27日在公司A栋C会议室以现场和通讯相结合的方式召开。会议审议了《关于公司 2025年半年度报告及其摘要的议案》等文件。 （记者 张喜威） 2024年1至12月份，塞力医疗的营业收入构成为：商业占比97.09%，工业占比2.91%。 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 ...